BPTH News and Press, Bio-Path Holdings Inc.

Marks Meaningful Progress Across Key Clinical Trials in Multiple Cancer Indications Completes Development of Oncology Molecular Biomarkers and Prepares for Preclinical Obesity Studies HOUSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnolog...

2024-06-17 10:10:00 ET June 17, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the first of a two-part series looking at developments for the treatment of blood cancers. Today's snapshot focuses in on acute myeloid leukemia (AML) and the compan...

2024-06-17 09:45:40 ET Palm Beach, FL – June 17, 2024 – According to a report from Mordor Intelligence the Acute Myeloid Leukemia Market size is estimated at USD 1.83 billion in 2024, and is expected to reach USD 2.97 billion by 2029, growing at a CAGR of 10.15% during the...

2024-06-14 12:12:17 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Onsemi (NASDAQ: ON ) layoffs are a hot topic on Friday as the semiconductor company has announced plans to cut 1,000 jobs . A statement from Onsemi notes that these cuts wil...

2024-06-14 11:50:49 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Hasbro (NASDAQ: HAS ) stock could be poised for further gains if Bank of America analysts are right about the toy and game company’s shares. Bank of America analysts in...

2024-06-14 11:30:44 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Bio-Path (NASDAQ: BPTH ) stock is rising higher on Friday alongside data from the oncology-focused company’s Phase 2 clinical trial of prexigebersen. Prexigebersen&#x...

A look at the top 10 most actives in the United States SRIVARU Holding Limited (SVMH) rose 94.8% to $0.2971 on volume of 77,516,058 shares NVIDIA Corporation (NVDA) fell 0.3% to $129.16 on volume of 39,120,242 shares Longeveron Inc. (LGVN) rose 27.0% to $3.415 on volume of 36,214,736 shar...

HOUSTON, June 14, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize ® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, presented interim results from the C...

2024-06-12 05:14:22 ET More on Bio-Path Bio-Path announces $4.0 million private placement Bio-Path announces $1.2M registered direct offering priced at-the-market Seeking Alpha’s Quant Rating on Bio-Path Historical earnings data for Bio-Path ...

HOUSTON, June 05, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ:BPTH) (“Bio-Path” or the “Company”), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic aci...